IL-2 for Multi Drug Resistant Nephrotic Syndrome

Key facts

Sponsor

Istituto Giannina Gaslini

Principal Investigator

Gian Marco Ghiggeri, MD

Istituto Giannina Gaslini

Intervention

Proleukin®(drug)

Enrollment

5 target

Eligibility

2-18 years · All sexes

Timeline

2012 – 2012

Study locations (1)

• Istituto Giannina Gaslini, Genova, Italy, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Idiopathic nephrotic syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06820866
  Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
  Assistance Publique - Hôpitaux de Paris
• ACTIVE NOT RECRUITINGPHASE3NCT05627557
  A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
  Hoffmann-La Roche
• RECRUITINGNCT04207580
  A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
  University Hospital, Limoges

See all trials for Idiopathic nephrotic syndrome →